[ivory-search id="184" title="Recordati AJAX Search Form"]

Our Story

Recordati established rare diseases operations in the Nordic and Baltic regions in 2007 as part of Recordati Rare Diseases. In 2018 the Recordati Speciality and Primary Care business unit was incorporated together with the Rare Disease business unit in Recordati AB. Today Recordati AB operates across the Nordic and Baltic regions from our regional office in Stockholm, Sweden.

Our Story

Recordati was established in the Nordic and Baltic regions with the rare diseases portfolio in 2007 due to the acquisition of Orphan Europe. In 2018 the Recordati Speciality and Primary Care business unit was incorporated together with the Rare Disease business unit in Recordati AB. Today Recordati AB operates across the Nordic and Baltic regions from our regional office in Stockholm, Sweden.

Recordati will bring treatment options across specialty and primary care and rare diseases business units, and has operations worldwide, including here in the Nordics-Baltics with a well-diversified portfolio of prescription drugs, available to healthcare professionals and patients, and offered in most Nordics-Baltics markets.

Our purpose and corporate philosophy is to give people the opportunity to unlock the full potential of life and to bring a brighter future to patients across the world.

We believe that health, and the opportunity to live life to the fullest, is a right, not a privilege.

Specialty and Primary care Nordics focuses mainly on the following therapeutical areas: cardiovascular, central nervous system, gastrointestinal, urological.

Recordati is a global international pharmaceutical company, Headquartered in Milan, Italy and listed on the Italian stock exchange. With over 4,450 employees, we develop and commercialise medicines to serve people living with common diseases, as well as those living with some of the rarest, in around 150 countries.

 

The Nordics-Baltics headquarter operates from Stockholm and consists of 24 employees within commercial, medical, finance, supply chain, regulatory and QA.

Focused on the few.

 

The Rare Diseases business unit is focused on providing the most effective treatment for unmet medical needs, mainly of genetic origin and caused by metabolic disorders, endocrine diseases, rare oncology pathologies.

Underpinned by a history of strong financial delivery, we will continue to grow from within, capture opportunities within our own pipeline, and identify opportunities to bring in new treatments through partnerships & acquisitions across all our businesses.

MILESTONES

You are now leaving Recordati Nordic’s and Baltic’s page and will be linked to the Recordati global careers website

You are now leaving Recordati Nordic’s and Baltic’s page and will be linked to the Recordati global website

You are now leaving Recordati Nordic’s and Baltic’s page and will be linked to the Recordati global website

You are now leaving Recordati Nordic’s and Baltic’s page and will be linked to the Recordati global website

You are now leaving Recordati Nordic’s and Baltic’s page and will be linked to the Recordati global website

You are now leaving Recordati Nordic’s and Baltic’s page and will be linked to the Recordati global website

INFORMATION ON PERSONAL DATA PROTECTION PURSUANT TO ARTICLE 13 OF LEGISLATIVE DECREE NO. 196/2003

The personal data that you provide by compiling this form will be used by Recordati Industria Chimica e Farmaceutica S.p.A. (“Recordati”) – the “Data Controller” – solely for performing activities connected with the provision of the email alert service and it will be processed manually, by computer and via the internet in a manner that will guarantee its security and confidentiality. It is not compulsory for you to give your data, however, if you refuse to allow it to be processed, then it will be impossible for Recordati to provide you with the above-mentioned service. Your personal data may be passed on to other companies that belong to the RECORDATI Group or to associate companies of the Group and to third parties that Recordati uses to provide the service to you.

 

In any event we assure you that your data will be processed solely for the above purposes and using the above methods.

 

The company Tech Style S.r.l. has been appointed as external Data Processor in accordance with Art. 29 of the Privacy Code, because it has been engaged to maintain the technological part of the website. The Director of Investor Relations and Corporate Communication of Recordati S.p.a. has been appointed as internal Data Processor of Recordati in accordance with article 29 of the Privacy Code.

 

A data subject shall have the right to obtain at any moment confirmation of whether or not data is held on him/her, to know its content and origin, to check its accuracy or to ask for it to be added to, updated or rectified (article 7 of the Privacy Code).

 

Requests must be sent to the Data Processor of Recordati:
   by email, to the address: INVER@recordati.it;
   or by ordinary mail to Recordati Industria Chimica e Farmaceutica S.p.A. – Director of Investor Relations and Corporate Communications – 1 Via Civitali – 20148 Milan.

 

In accordance with article 23 of Legislative Decree No. 196/03 on personal data protection, having read the above information, I hereby authorise Recordati S.p.A. to process my personal data for the purposes set out in that same information. I am aware that if I refuse, Recordati will not be able to enable its email alert service for me.

 

Subsequent withdrawal of consent to the data processing mentioned in the preceding paragraph will result in the cancellation of the subscription request or cancellation of the subscription to the email alert service.